Top Markets
Coin of the day
Homology Medicines, Inc. Homology Medicines, Inc.

Homology Medicines, Inc.

FIXX
株式のランク #39911
Homology Medicines, Inc. is a biotechnology firm dedicated to genetic... Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.
株価
$0.9347
最終同期: 2024-03-25
時価総額
$300.42K
変化(1日)
0.75%
変化(1年)
0.00%
US
取引 Homology Medicines, Inc. (FIXX)

カテゴリー

Homology Medicines, Inc.(FIXX)のP/B比率
2026 時点のP/B比率 TTM: 0
Homology Medicines, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Homology Medicines, Inc. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE